CSPC PHARMACEUTICAL (CVG.SG)
CSPC PHARMACEUTICAL (CVG.SG) operates in Diversified Metals & Mining.
CSPC PHARMACEUTICAL (CVG.SG) (CVG) - Total Assets
Latest total assets as of December 2023: €46.28 Billion EUR
Based on the latest financial reports, CSPC PHARMACEUTICAL (CVG.SG) (CVG) holds total assets worth €46.28 Billion EUR as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CSPC PHARMACEUTICAL (CVG.SG) - Total Assets Trend (2016–2023)
This chart illustrates how CSPC PHARMACEUTICAL (CVG.SG)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CSPC PHARMACEUTICAL (CVG.SG) - Asset Composition Analysis
Current Asset Composition (December 2023)
CSPC PHARMACEUTICAL (CVG.SG)'s total assets of €46.28 Billion consist of 57.8% current assets and 42.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 26.0% |
| Accounts Receivable | €5.87 Billion | 12.7% |
| Inventory | €3.14 Billion | 6.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.20 Billion | 4.8% |
| Goodwill | €234.90 Million | 0.5% |
Asset Composition Trend (2016–2023)
This chart illustrates how CSPC PHARMACEUTICAL (CVG.SG)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC PHARMACEUTICAL (CVG.SG)'s current assets represent 57.8% of total assets in 2023, an increase from 57.1% in 2016.
- Cash Position: Cash and equivalents constituted 26.0% of total assets in 2023, up from 21.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
CSPC PHARMACEUTICAL (CVG.SG) Competitors by Total Assets
Key competitors of CSPC PHARMACEUTICAL (CVG.SG) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
XIWANG SPECIAL STEE (2XI.SG)
STU:2XI
|
Germany | €15.07 Billion |
|
LINDT & SPRUENGLI N - Dusseldorf Stock Exchang
DU:LSPN
|
Germany | €7.86 Billion |
|
PRICELINE.COM
BE:PCE1
|
Germany | €27.98 Billion |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
Germany | €27.98 Billion |
|
MURPHY USA
BE:1MU
|
Germany | €4.40 Billion |
|
RESMED (RME.SG)
STU:RME
|
Germany | €7.22 Billion |
|
DIOS EXPLORATIONS
BE:BFM
|
Germany | €7.25 Million |
|
CHINA YUCHAI INTL (CYD.SG)
STU:CYD
|
Germany | €25.76 Billion |
CSPC PHARMACEUTICAL (CVG.SG) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - CSPC PHARMACEUTICAL (CVG.SG) generates 0.68x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, CSPC PHARMACEUTICAL (CVG.SG) generates $ 12.69 in net profit.
CSPC PHARMACEUTICAL (CVG.SG) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.63 | 2.67 | 2.12 |
| Quick Ratio | 2.32 | 2.39 | 1.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €16.56 Billion | € 15.00 Billion | € 6.91 Billion |
CSPC PHARMACEUTICAL (CVG.SG) - Advanced Valuation Insights
This section examines the relationship between CSPC PHARMACEUTICAL (CVG.SG)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.8% |
| Total Assets | €46.28 Billion |
| Market Capitalization | $9.58K USD |
Valuation Analysis
Below Book Valuation: The market values CSPC PHARMACEUTICAL (CVG.SG)'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CSPC PHARMACEUTICAL (CVG.SG)'s assets grew by 10.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CSPC PHARMACEUTICAL (CVG.SG) (2016–2023)
The table below shows the annual total assets of CSPC PHARMACEUTICAL (CVG.SG) from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €46.28 Billion | +10.80% |
| 2022-12-31 | €41.77 Billion | +20.23% |
| 2021-12-31 | €34.74 Billion | +15.53% |
| 2020-12-31 | €30.07 Billion | +14.26% |
| 2019-12-31 | €26.32 Billion | +13.58% |
| 2018-12-31 | €23.17 Billion | +28.72% |
| 2017-12-31 | €18.00 Billion | +36.20% |
| 2016-12-31 | €13.22 Billion | -- |